Aastrom Biosciences Inc Share Price Nasdaq
Equities
US00253U4040
Pharmaceuticals
Sales 2024 * | 239M 19.08B | Sales 2025 * | 299M 23.86B | Capitalization | 2.22B 177B |
---|---|---|---|---|---|
Net income 2024 * | 4M 319M | Net income 2025 * | 25M 1.99B | EV / Sales 2024 * | 9.3 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.43 x |
P/E ratio 2024 * |
576
x | P/E ratio 2025 * |
94.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 28/02/13 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 24/01/21 |
Michael Halpin
COO | Chief Operating Officer | 62 | 09/04/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 05/01/15 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 05/01/15 |
Robert Zerbe
CHM | Chairman | 73 | 15/01/06 |
1st Jan change | Capi. | |
---|---|---|
-4.03% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |